Elsevier

Biomaterials

Volume 275, August 2021, 120980
Biomaterials

Endothelin-1 enhances the regenerative capability of human bone marrow-derived mesenchymal stem cells in a sciatic nerve injury mouse model

https://doi.org/10.1016/j.biomaterials.2021.120980Get rights and content

Abstract

We expanded the application of endothelin-1 (EDN1) by treating human mesenchymal stem cell (hMSC) organotypic spinal cord slice cultures with EDN1. EDN1-treated hMSCs significantly enhanced neuronal outgrowth. The underlying mechanism of this effect was evaluated via whole-genome methylation. EDN1 increased whole-genome demethylation and euchromatin. To observe demethylation downstream of EDN1, deaminases and glycosylases were screened, and APOBEC1 was found to cause global demethylation and OCT4 gene activation. The sequence of methyl-CpG-binding domain showed similar patterns between EDN1- and APOBEC1-induced demethylation. SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 4 (SMARC A4) and SMARC subfamily D, member 2 (SMARC D2) were screened via methyl-CpG-binding domain sequencing as a modulator in response to EDN1. Chromatin immunoprecipitation of the H3K9me3, H3K27me3, and H3K4me4 binding sequences on the APOBEC1 promoter was analyzed following treatment with or without siSMARC A4 or siSMARC D2. The results suggested that SMARC A4 and SMARC D2 induced a transition from H3K9me3 to H3K4me3 in the APOBEC1 promoter region following EDN1 treatment. Correlations between EDN1 pathways and therapeutic efficacy in hBM-MSCs were determined in a sciatic nerve injury mouse model. Thus, EDN1 may be a useful novel-concept bioactive peptide and biomaterial component for improving hMSC regenerative capability.

Introduction

Mesenchymal stem cells (MSCs) represent a promising tool for cell therapy as they can be easily isolated and cryo-stored, thus maintaining viability and regenerative capacity with low immunogenicity [1]. However, major challenges remain, including therapeutic efficacy and MSC production, which must be overcome before human MSCs (hMSCs) can be applied in regenerative medicine [[2], [3], [4]]. One of the limitations of current stem-cell-based approaches is that they require the use of substantial cell numbers [5]. Furthermore, clinical applications of hMSCs are hampered by the limited self-renewal ability of these cells in vitro and low activity in vivo [5]. However, this issue may be solved by identifying the priming factors that significantly enhance the regenerative capability of stem cells in vivo. Indeed, improved engraftment and therapeutic efficacy have been reported in MSCs primed by hypoxia, chemical agents, cytokines, or physical factors prior to application [[6], [7], [8], [9], [10], [11]].

In early passages, MSCs are small, spindle-shaped cells with a high proliferative capacity and differentiation potential [12]. During repetitive expansion in vitro, MSCs undergo so-called replicative senescence characterized by enlargement, thereby losing their self-renewal ability and differentiation potency [13,14]. Numerous studies have indicated an increased level of intracellular reactive oxygen species (ROS) as one of the several factors associated with replicative senescence. ROS accumulation plays a role in DNA/RNA modifications that lead to MSC senescence [15]. This observation supports studies aimed at reducing ROS generation, such as treatment of hBM-MSCs with antioxidants or culture under hypoxic conditions [16,17]. However, surplus factors that are mostly regulated by epigenetic phenomena are primarily involved in MSC senescence [10].

Changes in DNA methylation including down-regulation of OCT4 are also associated with replicative senescence [18,19]. Interestingly, iPSC derived MSCs were shown to have erased senescence-related DNA methylation patterns and exhibited epigenetic rejuvenation [19].

OCT4 is known to function in the maintenance of self-renewal properties and has an undifferentiated status in MSCs [20]. During repetitive cell divisions and proliferation in vitro, the expression of OCT4 is down-regulated. Certain conditions, such as serum deprivation or culture under hypoxia, increase OCT4 expression in MSCs [21,22].

Epigenetic changes can be reversed via priming [23,24]. These epigenetic modifications then affect gene expression and thus the therapeutic efficacy of hMSCs [23]. Within mammals, methylation of cytosines at DNA cytosine-phosphate-guanine (CpG) sites account for one of the primary mechanisms of epigenetic variation. Specifically, methylation of CpG sites in promoter regions leads to suppression of transcriptional activation. Furthermore, H3K4me3, H3K9me3, and H3K27me3 dynamic histone methylations were reported to be correlated with transcriptional changes [25,26]. Particularly, H3K4me3 is increasingly detected at active promoter regions and considered as an epigenetic marker of transcription activation [27]. In contrast, H3K27me3 and H3K9me3 are heterochromatin-associated signatures associated with transcriptional suppression [28].

We found that much of endothelin-1 (EDN1) was secreted from MSC clones and exhibited effective therapeutic efficacy in a rat myocardial infarction (MI) model by inducing up-regulation of cadherin 2 and vascular endothelial growth factor (VEGF) expression in MSCs [4]. Although EDN1 has been well-characterized as a 21-amino acid vaso-constricting peptide produced primarily in the endothelium and controls vascular tone [29], we examined its role in altering the epigenetic environment when added as a priming factor to hMSCs to improve their regenerative capability.

Section snippets

hBM-MSC culture and treatment

hBM-MSCs (Lonza, Basel, Switzerland) were grown in Mesenchymal Stem Cell Growth Media (MSCGM; Lonza) at 37 °C in an atmosphere with 5% CO2. hBM-MSCs at passages 7–8 were used in the experiments. The cells were treated with EDN1 (0.025 or 0.25 μg/mL, cat. no. E7764-10UG; Sigma Aldrich) for 24 h. APOBEC1 plasmid (Cat. SC303051; Origene) was transfected into the cells for 24 h using Lipofectamine 2000 and then used for analysis. To knock down APOBEC1, SMARCA4, and SMARCD2, hBM-MSCs were first

EDN1-treated hMSCs enhance neuronal outgrowth from rat spinal cord slice under ex vivo co-culture conditions

To determine the therapeutic applicability of EDN1-treated hMSCs, we performed ex vivo co-culture containing spinal cord slices from rats with naïve hMSCs or EDN1-treated hMSCs.

We evaluated neurite outgrowth by immuno-histochemical staining of neuro-filament-M (NF-M), a major component of the neuronal cytoskeleton. Pre-treatment of hMSCs with EDN1 (0.025 or 0.25 μg/mL) for 24 h induced significantly greater neuronal outgrowth of rat spinal cord slices than that exhibited by naïve hMSCs (Fig. 1a

Mechanism of improvement of the regenerative potential of hMSCs by EDN1

In the current study, hMSCs that were pre-treated with EDN1 showed significantly enhanced therapeutic ability compared with that of naïve hMSCs in in vivo regeneration of the cut sciatic nerve as well as in induction of neurite outgrowths from the spinal cord under ex vivo culture conditions. This may have been because of the paracrine effects of EDN1-primed hMSCs as well as the cellular effect, which was corroborated by the finding that a few Schwann cells were positive for human cell surface

Author contributions

Conceptualization: E.J.L. and H.K. Methodology: E.J.L., I.H., H.P., D.M., J.N.P., K.C.K., A. C., H. Y., J. L., H.P. and M.C. Data analysis: E.J.L., I.H. and H.K. Writing of the original manuscript: E.J.L. and I.H. Review and editing of the manuscript: E.J.L. and H.K. All authors read and approved the final version of the manuscript.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgment

This work was supported by the Korea Health Technology R&D Project Strategic Center of Cell and Bio Therapy [grant number HI17C2085] and Korea Research-Driven Hospital [grant number HI14C1277] through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare (MHW), Republic of Korea.

The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References (55)

  • S.F.H. De Witte et al.

    Epigenetic changes in umbilical cord mesenchymal stromal cells upon stimulation and culture expansion

    Cytotherapy

    (2018)
  • J.S. Cho et al.

    Transplantation of mesenchymal stem cells enhances axonal outgrowth and cell survival in an organotypic spinal cord slice culture

    Neurosci. Lett.

    (2009)
  • J. Chen et al.

    Hierarchical Oct4 binding in concert with primed epigenetic rearrangements during somatic cell reprogramming

    Cell Rep.

    (2016)
  • N. Singhal et al.

    Chromatin-remodeling components of the BAF complex facilitate reprogramming

    Cell

    (2010)
  • C.A. Gifford et al.

    Transcriptional and epigenetic dynamics during specification of human embryonic stem cells

    Cell

    (2013)
  • E.J. Lee et al.

    Regeneration of peripheral nerves by transplanted sphere of human mesenchymal stem cells derived from embryonic stem cells

    Biomaterials

    (2012)
  • X.Z. Qin et al.

    Structure-function analysis of the human insulin-like growth factor binding protein-4

    J. Biol. Chem.

    (1998)
  • H.X. Niu et al.

    Recombinant insulin-like growth factor binding protein-4 inhibits proliferation and promotes differentiation of neural progenitor cells

    Neurosci. Lett.

    (2017)
  • Y.I. Rovira Gonzalez et al.

    In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter

    Cytotherapy

    (2016)
  • G.E. Neurohr et al.

    Excessive cell growth causes cytoplasm dilution and contributes to senescence

    Cell

    (2019)
  • L. Hayflick et al.

    The serial cultivation of human diploid cell strains

    Exp. Cell Res.

    (1961)
  • T. Trost et al.

    Characterizing the role of SWI/SNF-related chromatin remodeling complexes in planarian regeneration and stem cell function

    Stem Cell Res.

    (2018)
  • E.J. Lee et al.

    Novel embryoid body-based method to derive mesenchymal stem cells from human embryonic stem cells

    Tissue Eng.

    (2010)
  • W. Wagner et al.

    Different facets of aging in human mesenchymal stem cells

    Tissue Eng. B Rev.

    (2010)
  • C. Hu et al.

    Preconditioning influences mesenchymal stem cell properties in vitro and in vivo

    J. Cell Mol. Med.

    (2018)
  • X.Y. Hu et al.

    A Large-scale investigation of hypoxia-preconditioned allogeneic mesenchymal stem cells for myocardial repair in nonhuman primates

    Circ. Res.

    (2016)
  • N. Noiseux et al.

    Preconditioning of stem cells by oxytocin to improve their therapeutic potential

    Endocrinology

    (2012)
  • Cited by (0)

    View full text